A Model for Measuring the Health Burden of Classic Congenital Adrenal Hyperplasia in Adults

Article English OPEN
Hummel, S.R. ; Sadler, S. ; Whitaker, M.J. ; Ara, R.M. ; Dixon, S. ; Ross, R.J. (2016)
  • Publisher: Wiley
  • Subject:
    mesheuropmc: endocrine system diseases

Aim Patients with classic congenital adrenal hyperplasia (CAH)have poor health outcomes. In the absence of a comprehensive observational study, this manuscript provides a model to esti-mate the lifetime disease burden of adults with classic CAH. Methods The model, built in Excel, comprises subdomains addressing the health consequences of CAH and synthesises evidence from clinical and epidemiological studies on health out-comes.Results The model estimates that adults with classic CAH will implement ‘sick day rules’ (doubling or tripling glucocorticoid and/or use of parenteral therapy) 171 times over their lifetime and attend hospital for adrenal crisis on 11 occasions. In a population of 1000, over 200 will die of a condition complicated by adrenal crisis resulting, on average, in a loss of 7 years of life.Patients with CAH may also suffer from excess CVD events.Treatment with glucocorticoids almost doubles the risk of bone fractures in patients with CAH compared to the general popula-tion, leading on average to an additional 08 fractures perpatient with CAH over their lifetime.Conclusions The disease burden model highlights gaps in evidence, particularly regarding intensity of care and adrenal crisis,and the relationship between control of CAH and risks of CVD, osteoporosis, diabetes and infertility. The model can be used for research on the impact of new clinical pathways and therapeutic interventions in terms of clinical events and cost.
  • References (36)
    36 references, page 1 of 4

    1 Pang, S.Y., Wallace, M.A., Hofman, L. et al. (1988) Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics, 81, 866-874.

    2 Merke, D.P. & Bornstein, S.R. (2005) Congenital adrenal hyperplasia. Lancet, 365, 2125-2136.

    3 Arlt, W., Willis, D.S., Wild, S.H. et al. (2010) Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. Journal of Clinical Endocrinology and Metabolism, 95, 5110-5121.

    4 Finkielstain, G.P., Kim, M.S., Sinaii, N. et al. (2012) Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. The Journal of Clinical Endocrinology and Metabolism, 97, 4429-4438.

    5 Han, T.S., Walker, B.R., Arlt, W. et al. (2014) Treatment and health outcomes in adults with congenital adrenal hyperplasia. Nature Reviews. Endocrinology, 10, 115-124.

    6 Nermoen, I., Husebye, E.S., Svartberg, J. et al. (2010) Subjective health status in men and women with congenital adrenal hyperplasia: a population-based survey in Norway. European Journal of Endocrinology, 163, 453-459.

    7 J€a€askel€ainen, J. & Voutilainen, R. (2000) Long-term outcome of classical 21-hydroxylase deficiency: diagnosis, complications and quality of life. Acta Paediatrica, 89, 183-187.

    8 Weinstein, M.C., Torrance, G. & McGuire, A. (2009) QALYs: the basics. Value Health, 12(Suppl 1), S5-S9.

    9 Gold, M., Franks, P. & Erickson, P. (1996) Assessing the health of the nation. The predictive validity of a preference-based measure and self-rated health. Medical Care, 34, 163-177.

    10 Statisics, O.o.N. (2013) Interim life tables 2009-2011.

  • Metrics
    views in OpenAIRE
    views in local repository
    downloads in local repository

    The information is available from the following content providers:

    From Number Of Views Number Of Downloads
    White Rose Research Online - IRUS-UK 0 16
Share - Bookmark